Alcon faces setback on experimental AMD therapy

Shares of Alcon slipped this morning after the eye care giant announced that the FDA would require another trial of its experimental therapy for wet, age-related macular degeneration. Researchers for the company said there were no plans to mount a new trial of Retaane, due to the difficulty of finding volunteers and the presence of other therapies on the market. But it will wrap another trial of Retaane in three months which is focused on the drug's ability to prevent the disease from progressing from the dry form of age-related macular degeneration to the wet form.

- see Alcon's release for more

Related Articles:
Regeneron, Genentech go head-to-head. Report
Doctors balancing effects, costs of Lucentis and Avastin. Report
Lucentis beats Visudyne in trial. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.